SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the metabolomics changes associated with dapagliflozin treatment in
patients with type 2 diabetes mellitus (T2DM). The participants in the study will be
randomized to receive 10 mg dapagliflozin or placebo once daily for 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud